Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
February 16, 2024 15:19 ET
|
Iovance Biotherapeutics, Inc.
AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune...
Bragar Eagel & Squire, P.C. Is Investigating Evolus, Lizhi, Iovance Biotherapeutics, and Y-mAbs Therapeutics and Encourages Investors to Contact the Firm
October 09, 2020 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against on behalf of investors of Evolus,...
Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer
July 18, 2019 08:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on...